NancyUan-TsinLinMD

Breast Cancer

Associate Professor of Medicine, Harvard Medical School; Associate Chief, Division of Breast Oncology Center, Dana-Farber Cancer Institute

Join to view full profile

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile

Already have an account?

Office
44 Binney St
# Dana-Far
Boston, MA 02115
Phone+1 617-632-3800

Fax+1 617-632-1930

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

Certifications & Licensure

FL State Medical License 2022 - Present
VT State Medical License 2023 - 2026
MA State Medical License 2002 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer Start of enrollment: 2007 May 14
Active, not recruiting
Phase 2
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer Start of enrollment: 2007 Apr 01
Completed
Phase 1
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Start of enrollment: 2007 Nov 01
Terminated
Phase 3
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases Start of enrollment: 2009 Nov 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer Start of enrollment: 2011 Aug 01
Completed
Phase 1, Phase 2
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Start of enrollment: 2011 Oct 01
Completed
Phase 2
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 2
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
BKM120 For Triple Negative Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets Start of enrollment: 2013 Aug 01
Completed
Phase 1
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 1, Phase 2
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer Start of enrollment: 2016 Apr 07
Completed
Phase 2
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Start of enrollment: 2018 May 21
Active, not recruiting
Phase 2
Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer Start of enrollment: 2019 Sep 16
Suspended
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer.
Shoshana M Rosenberg, Yue Zheng, Katheryn Santos, Elizabeth Riley, Hugh Wallace Meadows
Breast Cancer Research and Treatment. 2025-02-01
Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the Surveillance, Epidemiology, and End Results database...
Adrienne G Waks, Paolo Tarantino, Emily L Chen, Rachel A Freedman, Nancy U Lin
Cancer. 2025-02-01
1 citations
Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.
Alyssa M Pereslete, Melissa E Hughes, Alyssa R Martin, Janet Files, Kyleen Nguyen
Neuro-Oncology. 2025-01-12

Journal Articles

Attitudes of Patients with Metastatic Cancer Towards Research Biopsies
Nancy Lin, MD, Asia‐Pacific Journal of Clinical Oncology

Press Mentions

CBD Trial Shows Promise for Cancer Anxiety ReliefDecember 17th, 2024
Managing Central Nervous System Metastasis in Patients with HER2-Positive Breast CancerOctober 22nd, 2024
T-dXd Demonstrated Intracranial Activity in HER2+ Breast CancerOctober 5th, 2024
Join now to see all